BoobyBiome
Overview
BoobyBiome is a biotechnology company focused on improving infant health by harnessing the microbiome of breast milk. Founded in 2019 by Dr. Lydia Mapstone, Dr. Sioned Jones, and Dr. Tara O'Driscoll, the company is based in London, UK. BoobyBiome has raised significant funding, most recently securing €2.8 million in seed funding. The company aims to address modern infant health challenges by ensuring access to the beneficial microbiomes found in breast milk, whether for breastfeeding, formula-fed or pre-term infants.
Recent Developments
- September 2025: BoobyBiome raised €2.8 million in seed funding to advance its infant feeding solutions, develop its storage device, and scale its operations internationally. This funding will drive research and development efforts and the commercial launch of its storage device and microbiome drop.
- January 2025: The company was shortlisted for the 2025 RFSI Europe Pitching Event in Brussels, gaining recognition in the Food as Healthcare category for its innovative approach to improving infant health through breast milk microbiome.
- December 2024: Co-founders Dr. Lydia Mapstone, Dr. Sioned Jones, and Dr. Tara O'Driscoll were recognized in the Hurun UK Under 30 list, highlighting their contributions to the biotech sector.
These developments reflect BoobyBiome's ongoing commitment to improving infant health through cutting-edge science and innovative product development.
Company Information
| Attribute | Information |
|---|---|
| Founding Date | 2019 |
| Headquarters | London, UK |
| Founders | Dr. Lydia Mapstone, Dr. Sioned Jones, Dr. Tara O'Driscoll |
| Revenue | Not publicly disclosed |
| Profits | Not publicly disclosed |
| Key Investors | Empirical Ventures, The Helm, XFactor Ventures, Lavender Ventures, Kayan Ventures, Evenlode Investment |
| Industry | Biotechnology |
| Number of Employees | 10 |
Early History
BoobyBiome was founded in 2019, emerging from groundbreaking research conducted at UCL’s Institute of Child Health. The founders, all female scientists, were motivated by increasing rates of infant health issues associated with inadequate microbiome development. Recognizing the critical role of beneficial bacteria in breast milk, they established BoobyBiome to leverage this research in developing solutions that support infant health. Early efforts focused on creating a comprehensive breast milk microbiome database, a pioneering move that underscored their commitment to science-driven innovation.
Company Profile and Achievements
BoobyBiome's business model centers around translating scientific research on the breast milk microbiome into practical health solutions. Key achievements include:
- Innovation in Infant Health: BoobyBiome developed a patented breast milk storage device that preserves the live microbiome and essential nutrients soon after milk expression. This device aims to mitigate early-life health risks such as allergies and asthma.
- Database and Biobank Development: The company built the world's largest high-resolution breast milk microbiome database and a biobank of proprietary bacterial strains, crucial for infant gut and immune system development.
- Global Recognition: Its inclusion in the Hurun UK Under 30 list and shortlisting for the RFSI Europe Pitching Event in 2025 underscore BoobyBiome's impact in the biotech field.
- Strategic Funding and Partnerships: Regular injection of funds, including the €2.8 million raised in 2025, supports its research and international scaling efforts, with established partnerships with global infant bottle manufacturers.
Current Operations and Market Position
Currently, BoobyBiome is scaling up its operations to make its innovations widely accessible. They are preparing for the 2026 commercial launch of their breast milk storage device in the UK, with plans to expand into European and US markets. The company continues clinical trials for its live microbiome drop, aiming to bridge health gaps in non-breastfed infants. BoobyBiome’s strategic focus on product effectiveness and safety, supported by a robust scientific foundation, places it at the forefront of infant health innovation.
Conclusion
BoobyBiome represents a pioneering effort in using biotechnological advancements to tackle pressing infant health issues, by optimizing the health benefits inherent within breast milk. Through its innovative products and ample research foundation, the company aims to offer transformative solutions globally. As it gains further traction and funding, BoobyBiome has the potential to make substantial contributions to the global biotech sector, set to redefine infant nutrition and health. The company is poised to increase its influence, potentially impacting policies and standards regarding infant nutrition across the industry.